ESAIY / Merck and Eisai cull late-stage study for head and neck cancer therapy

This segment originally aired on October 26, 2023. Eisai has (EISAY) reported positive results in clinical trials of their Alzheimer's drug- Leqembi. more_horizontal

Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet thei more_horizontal

Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF more_horizontal

Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head more_horizontal

Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage trial of a treatment for head and neck cancer fail more_horizontal

Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and more_horizontal

The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the more_horizontal

TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the more_horizontal